Provided by Tiger Trade Technology Pte. Ltd.

Bausch + Lomb Corp.

18.30
+0.42002.35%
Volume:70.43K
Turnover:1.28M
Market Cap:6.52B
PE:-38.02
High:18.44
Open:17.94
Low:17.87
Close:17.88
52wk High:18.92
52wk Low:13.77
Shares:356.38M
Float Shares:45.50M
Volume Ratio:0.83
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4814
EPS(LYR):-1.0200
ROE:-2.52%
ROA:1.83%
PB:1.02
PE(LYR):-17.94

Loading ...

GUIDANCE: (BLCO) Bausch + Lomb Expects Full Year 2026 Revenue Range $5.44B - $5.54B, vs. FactSet Est of $5.47B

MT Newswires Live
·
Jul 29

Bausch + Lomb Q2 Adjusted EPS USD 0.15 Vs. IBES Estimate USD 0.15

Reuters
·
Jul 29

Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate

Benzinga Earnings
·
Jul 29

Bausch + Lomb Q2 FY26 GAAP Net Loss Narrows to $14 Million; Revenue Rises 9% to $1.39 Billion

Reuters
·
Jul 29

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Simply Wall St.
·
Jul 29

Bausch + Lomb Corp Expected to Post Earnings of 15 Cents a Share - Earnings Preview

Reuters
·
Jul 27

Earning Preview: Bausch + Lomb Corp. this quarter’s revenue is expected to increase by 8.79%, and institutional views are bullish

Earnings Agent
·
Jul 22

Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo

TIPRANKS
·
Jul 22

Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says

MT Newswires Live
·
Jul 20

Bausch + Lomb launches EyeGility Inserter in U.S.

TIPRANKS
·
Jul 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Jul 16

Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint

TIPRANKS
·
Jul 10

Bausch + Lomb Releases Phase 2 Bl1107 Glaucoma Study Update

Reuters
·
Jul 10

Bausch + Lomb Launches AI-Powered Digital Health Platform Orphia to Refocus Eye Care on Patient Treatment

Deep News
·
Jul 09

Bausch + Lomb introduces Orphia AI-powered digital health platform

TIPRANKS
·
Jul 09

Bausch + Lomb price target raised to $21 from $19 at Citi

TIPRANKS
·
Jul 08

Citi Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
Jul 08

Bausch + Lomb Schedules Q2 2026 Financial Results Release for July 29

Deep News
·
Jul 06

Bausch + Lomb Survey Links Dry Eye Symptom Treatment to Improved Quality of Life, Lower Anxiety

Reuters
·
Jul 01

Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Recent Share Price Weakness And Governance Concerns

Simply Wall St.
·
Jun 01